Replies to post #24358 on Innovation Pharmaceuticals Inc (IPIX)

[58nout]

TOB, as always, right you are. The question here is would the management of this company proceed with the necessary expenditures if it was not necessary in order to move several trials forward as necessary to their completion and ultimate success. I think not. This is NOT C---! Hold tight, it's coming.

GO CTIX!

[BonelessCat]

So it is game on for the Prurisol and additional Kevetrin trials, and more preclinical research for Kevetrin.

Exactly, but I'm just too brain dead from a difficult week to be so articulate.

I would expect the declaration to be received as good news the same way that the original deal was received with significantly higher valuation following its announcement. Toss in some news before Tuesday opening and we have the makings for a week of recovery.

Those who received the RSS feed took this as news of new dilution and does explain the selling pattern today. But, I think anyone still short for the long weekend will be paying a price for that position come Tuesday.

[keltoi]

Huger??? :) OOOO,,,KKKKKK
To quote "The Fonze","Correctamundo!!!"

If a "pea-brained" investor like myself can figure that out then , maybe I'm smarter than I give myself credit for.
CTIX investing is like an ocean voyage.You float up on the swells and drop down in the troughs but that's not the object of the voyage.It's the destination that counts.
The ups and downs mean nothing as long as you reach your target destination.
Not knowing the destination makes the voyage an effort in futility
for those who just want to trade,who don't know where this ship is headed.If they knew where this ship was headed and the news cycle coming they would be too afraid to trade.Bad DD works both ways.

Kelt

[loanranger]

I only gave the Q a brief scan, but as regards your quote:

"Requirement for Additional Capital

Research and Development Costs. The Company has engaged in limited research and development activities. We currently do not have sufficient funds to meet our planned drug development for the next twelve (12) months and we may not be able to obtain the necessary financing on terms and conditions acceptable to the Company. Assuming that we are successful in raising additional financing, we plan to incur the following expenses over the next twelve (12) months:

1. Research and Development- $2,000,000 in preclinical development costs, including testing Kevetrin on additional tumors and costs to manufacture Prurisol.

2. Clinical trials – $3,000,000. We have budgeted $1,500,000 for our Phase 1 Kevetrin trials and $1,500,000 for the Prurisol pilot study and phase 2/3 trials.

3. Corporate overhead of $1,250,000: Budgeted office salaries, legal, accounting and other costs expected to be incurred.

4. Capital costs of $100,000: Estimated cost for equipment and laboratory improvements."


It doesn't reflect the existing net negative working capital of ~$7.4M. Some of that....a lot I guess....is based on amounts due to officers (and related parties?) who have shown some evidence of a willingness to wait, but in the interest of completeness can't be excluded from ""Requirement for Additional Capital". I won't comment further without a more careful review.